John Vickery, MD
Allergy & Immunology · Newnan, GANPI 1336364793
Payments from drug & device makers
Across 344 payments — averaging $35.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$2K
- AstraZeneca$2K
- Blueprint Medicines Corporation$2K
- GSK$1K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $4K from 30 others
What the payments were for
- Consulting fees$1,81215%
- Speaking & faculty fees$1,74314%
- Food & beverage$8,43669%
- Education$1531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 2 | $1,825 |
| AstraZeneca | 49 | $1,579 |
| Blueprint Medicines Corporation | 13 | $1,568 |
| GSK | 61 | $1,215 |
| Sanofi | 42 | $1,215 |
| Regeneron Healthcare Solutions, Inc. | 32 | $1,011 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $573 |
| Aimmune Therapeutics, Inc. | 4 | $571 |
| Biocryst US Sales Co., LLC | 23 | $406 |
| Novartis | 10 | $315 |
| Grifols USA, LLC | 12 | $286 |
| CSL Behring | 9 | $229 |
| Pharming Healthcare, Inc. | 8 | $221 |
| Sanofi-aventis U.S. LLC | 2 | $145 |
| Optinose US, Inc. | 5 | $104 |
| AbbVie | 3 | $87 |
| Pfizer | 4 | $85 |
| Kaleo, Inc. | 5 | $81 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $78 |
| Phadia US Inc. | 4 | $67 |
| Ionis Pharmaceuticals, Inc. | 3 | $65 |
| LEO Pharma Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Amgen | 3 | $45 |
| Genentech USA, Inc. | 2 | $44 |
| Incyte Corporation | 1 | $27 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| Dermavant Sciences, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Greer Laboratories, Inc. | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $18 |
| Verona Pharma, Inc. | 1 | $18 |
| Boston Scientific | 1 | $13 |
| Organon | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,144 in reported general payments places this provider in the 70th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 13 | $525,470 |
| XolairOmalizumab | 106 | $380,101 |
| NucalaMepolizumab | 25 | $194,825 |
| FasenraBenralizumab | 18 | $106,190 |
| TezspireTezepelumab-Ekko | 24 | $98,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $64,782 |
| Dupixent SyringeDupilumab | 16 | $60,168 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $49,843 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $26,070 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $24,716 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $8,530 |
| Epinephrine | 17 | $5,377 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,123 |
| Fluticasone Propionate | 150 | $2,562 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $1,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $406 | $525,47013 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta | $1,215 | $284,323177 claims |
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere, Symbicort | $1,579 | $238,924113 claims |
| Grifols USA, LLCGamunex-C | $286 | $49,84315 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $5,37717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Newnan
- Nathan SegallStockbridge$4.5M
- Tracy BridgesAlbany$1.5M
- Brad GoodmanSavannah$1.3M
- Michael BlaissRoswell$1.1M
- Robert ChrzanowskiColumbus$941K
- Stanley FinemanMarietta$855K
- Robert CartwrightColumbus$678K
- Deborah BirxAtlanta$470K
- Jack EadesMacon$282K
- Bruce FinkelSavannah$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.